Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609840 · ClinicalTrials.gov registry record
Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 25
- Enrollment target
NCT03609840 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 25 participants.
The verdict
NCT03609840 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Thiotepa is a chemotherapy drug used extensively in bone marrow transplantation. Thiotepa is a prodrug that undergoes metabolic conversion in the liver by CYP2B6 and CYP3A4 to its primary active metabolite, triethylene phosphoramide (TEPA). The goal of this study is to determine what causes some children to have different drug concentrations of thiotepa and TEPA in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that certain clinical and genetic factors cause changes in thiotepa and TEPA drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.
Interventions
- DRUG Thiotepa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-05-24 |
| Est. Completion | 2023-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03609840
The ClinicalTrials.gov registry entry for NCT03609840 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thiotepa is the first listed.
NCT03609840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03609840 about?
NCT03609840 is a clinical study titled "Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients". Thiotepa is a chemotherapy drug used extensively in bone marrow transplantation. Thiotepa is a prodrug that undergoes metabolic conversion in the liver by CYP2B6 and CYP3A4 to its primary active metabolite, triethylene phosphoramide (TEPA). The goal of this study is to determine what causes some chi...
What is the current status of trial NCT03609840?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2017-05-24. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT03609840?
The interventions under investigation include: Thiotepa (DRUG).
Who is sponsoring clinical trial NCT03609840?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.